Cargando…
SMAD4 Y353C promotes the progression of PDAC
BACKGROUND: SMAD4 is frequently inactivated and associated with a poor prognosis in pancreatic ductal adenocarcinoma (PDAC). Abnormal SMAD4 expression also plays an important role in the malignant progression of PDAC. METHODS: We investigated SMAD4 status in PDAC by immunohistochemical methods to ex...
Autores principales: | Wang, Zusen, Li, Yongxing, Zhan, Shixiong, Zhang, Lu, Zhang, Shun, Tang, Qian, Li, Miaomiao, Tan, Zhen, Liu, Shiguo, Xing, Xiaoming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6829834/ https://www.ncbi.nlm.nih.gov/pubmed/31684910 http://dx.doi.org/10.1186/s12885-019-6251-7 |
Ejemplares similares
-
Easy353: A Tool to Get Angiosperms353 Genes for Phylogenomic Research
por: Zhang, Zhen, et al.
Publicado: (2022) -
The role of survivin in the progression of pancreatic ductal adenocarcinoma (PDAC) and a novel survivin-targeted therapeutic for PDAC
por: Brown, Matthew, et al.
Publicado: (2020) -
SIRT 1 Overexpression is Associated with Metastasis of Pancreatic Ductal Adenocarcinoma (PDAC) and Promotes Migration and Growth of PDAC Cells
por: Li, Siqin, et al.
Publicado: (2016) -
Stromal and therapy-induced macrophage proliferation promotes PDAC progression and susceptibility to innate immunotherapy
por: Zuo, Chong, et al.
Publicado: (2023) -
Cell Lineage Infidelity in PDAC Progression and Therapy Resistance
por: Malinova, Antonia, et al.
Publicado: (2021)